---
schema_version: "secwatch.filing_event.v1"
accession: "0001641489-25-000010"
form_type: "8-K"
ticker: "VTVT"
cik: "0001641489"
company_name: "vTv Therapeutics Inc."
filed_at: "2025-03-17T23:59:59+00:00"
generated_at: "2026-05-24T15:44:22.806988+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# FDA lifts clinical hold on vTv Therapeutics' cadisegliatin Phase 3 diabetes trial

## Summary
- FDA lifted clinical hold effective March 14, 2025; CATT1 trial to resume after protocol amendment.
- Protocol amendment shortens trial from 12 to 6 months; primary endpoint (hypoglycemia rates) unchanged.
- Hold imposed July 26, 2024 due to chromatographic signal later found to be experimental artifact; no patients dosed.
- Cadisegliatin is a potential first-in-class oral adjunctive therapy to insulin for type 1 diabetes.
- Company expects shorter trial to expedite initiation of larger pivotal studies for NDA submission.

## SEC filing metadata
- accession: 0001641489-25-000010
- form_type: 8-K
- ticker: VTVT
- cik: 0001641489
- company_name: vTv Therapeutics Inc.
- filed_at: 2025-03-17T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1641489/000164148925000010/0001641489-25-000010-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1641489/000164148925000010/vtvt-20250314.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641489-25-000010
- JSON: https://secwatch.observer/filing/0001641489-25-000010.json
- Plain text: https://secwatch.observer/filing/0001641489-25-000010.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.